Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.43 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.43 |
| ▸ | TRPA1 | O75762 | 1/20 | 0.43 |
| ▸ | HSP90AA1 | P07900 | 1/20 | 0.41 |
| ▸ | PRCP | P42785 | 1/20 | 0.39 |
| ▸ | TSHR | P16473 | 1/20 | 0.38 |
| ▸ | NR4A1 | P22736 | 1/20 | 0.38 |
| ▸ | NR4A2 | P43354 | 1/20 | 0.38 |
| ▸ | NR4A3 | Q92570 | 1/20 | 0.38 |
| ▸ | GFER | P55789 | 1/20 | 0.38 |
| ▸ | CD44 | P16070 | 1/20 | 0.38 |
| ▸ | PNMT | P11086 | 1/20 | 0.38 |
| ▸ | KEAP1 | Q14145 | 1/20 | 0.38 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.38 |
| ▸ | HPGD | P15428 | 2/20 | 0.38 |
| ▸ | AURKA | O14965 | 1/20 | 0.38 |
| ▸ | CA12 | O43570 | 1/20 | 0.38 |
| ▸ | CA1 | P00915 | 1/20 | 0.38 |
| ▸ | CA2 | P00918 | 1/20 | 0.38 |
| ▸ | HMGB1 | P09429 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29662964 | 1.00 | ALDH1A1 (0.43) | ALDH1A1ALOX15TRPA1HSP90AA1PRCP | |
| SCHEMBL29801575 | 0.85 | PNMT (0.56) | PRCPCD44PNMT | |
| SCHEMBL5087669 | 0.85 | PNMT (0.56) | PRCPCD44PNMT | |
| SCHEMBL30744757 | 0.84 | CD44 (0.54) | ALDH1A1ALOX15TRPA1PRCPTSHR | |
| Hydrochloric Acid SCHEMBL17822916 | 0.84 | PNMT (0.54) | PRCPCD44PNMT | |
| SCHEMBL2329950 | 0.84 | CD44 (0.54) | ALDH1A1ALOX15TRPA1PRCPTSHR | |
| SCHEMBL2630741 | 0.83 | AURKA (0.51) | ALDH1A1ALOX15TRPA1TSHRCD44 | |
| SCHEMBL29945392 | 0.83 | AURKA (0.51) | ALDH1A1ALOX15TRPA1TSHRCD44 | |
| Hydrochloric Acid SCHEMBL30040239 | 0.81 | AURKA (0.50) | ALDH1A1ALOX15TRPA1TSHRCD44 | |
| SCHEMBL1871232 | 0.80 | CD44 (0.35) | TRPA1CD44PNMTAURKA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 35 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20110124705-A1 | PRODRUGS OF ALPHA-2-DELTA LIGANDS, PHARMACEUTICAL COMPOSITIONS AND USES THEREOF | XENOPORT, INC. (US) | 2011-05-26 | — | — | US | claimed |
| US-7053122-B2 | Therapeutic use of aryl amino acid derivatives | PFIZER INC (US) | 2006-05-30 | — | — | US | claimed |
| EP-1658059-A1 | A PHARMACEUTICAL COMPOSITION FOR THE TREATMENT OF OBESITY OR TO FACILITATE OR PROMOTE WEIGHT LOSS | Pfizer Products Inc. (US) | 2006-05-24 | — | — | EP | claimed |
| EP-1658058-A1 | A PHARMACEUTICAL COMPOSITION FOR THE PREVENTION AND TREATMENT OF ADDICTION IN A MAMMAL | Pfizer Products Inc. (US) | 2006-05-24 | — | — | EP | claimed |
| EP-1658098-A1 | PHARMACEUTICAL COMPOSITION COMPRISING AN ALPHA2DELTA LIGAND AND AN OPIOID RECEPTOR ANTAGONIST FOR THE PREVENTION AND TREATMENT OF ADDICTION IN A MAMMAL | Pfizer Products Inc. (US) | 2006-05-24 | — | — | EP | claimed |
| EP-1528919-A2 | THERAPEUTIC USE OF ARYL AMINO ACID DERIVATIVES | Pfizer Limited (GB) | 2005-05-11 | — | — | EP | claimed |
| WO-2005018622-A1 | A PHARMACEUTICAL COMPOSITION FOR THE TREATMENT OF OBESITY OR TO FACILITATE OR PROMOTE WEIGHT LOSS | PFIZER PRODUCTS INC. (US) | 2005-03-03 | — | — | WO | claimed |
| WO-2005018621-A1 | A PHARMACEUTICAL COMPOSITION FOR THE PREVENTION AND TREATMENT OF ADDICTION IN A MAMMAL | PFIZER PRODUCTS INC. (US) | 2005-03-03 | — | — | WO | claimed |
| WO-2005018670-A1 | PHARMACEUTICAL COMPOSITION COMPRISING AN ALPHA2DELTA LIGAND AND AN OPIOID RECEPTOR ANTAGONIST FOR THE PREVENTION AND TREATMENT OF ADDICTION IN A MAMMAL | PFIZER PRODUCTS INC. (US) | 2005-03-03 | — | — | WO | claimed |
| US-20050043407-A1 | Pharmaceutical composition for the prevention and treatment of addiction in a mammal | PFIZER INC | 2005-02-24 | — | — | US | claimed |
| US-20050043406-A1 | Pharmaceutical composition for the treatment of obesity or to facilitate or promote weight loss | PFIZER INC | 2005-02-24 | — | — | US | claimed |
| US-20050043345-A1 | Pharmaceutical composition for the prevention and treatment of addiction in a mammal | PFIZER INC | 2005-02-24 | — | — | US | claimed |
| US-20040138197-A1 | Therapeutic use of aryl amino acid derivatives | MAW GRAHAM NIGEL (GB) | 2004-07-15 | — | — | US | claimed |
| WO-2004014357-A2 | THERAPEUTIC USE OF ARYL AMINO ACID DERIVATIVES | PFIZER LIMITED (GB) | 2004-02-19 | — | — | WO | claimed |
| CN-112292370-A | Isoindolines as HDAC inhibitors | 瓦洛早期发现股份有限公司 | 2021-01-29 | — | — | CN | disclosed |
| EP-2877462-A1 | PROCESSES FOR PREPARING ISOINDOLINE-1,3-DIONE COMPOUNDS | Celgene Corporation (US) | 2015-06-03 | — | — | EP | disclosed |
| WO-2014018866-A1 | PROCESSES FOR PREPARING ISOINDOLINE-1,3-DIONE COMPOUNDS | CELGENE CORPORATION (US) | 2014-01-30 | — | — | WO | disclosed |
| WO-2004014357-A2 | THERAPEUTIC USE OF ARYL AMINO ACID DERIVATIVES | PFIZER LIMITED (GB) | 2004-02-19 | — | — | WO | disclosed |
| CN-1044912-C | Novel thio-substituted cyclic phosphonate compounds, pharmaceutical compositions, and methods for treating abnormal calcium and phosphate metabolism | PROCTER & GAMBLE PHARMA (US) | 1999-09-01 | — | — | CN | disclosed |
| CN-1086821-A | New thio-substituted cyclic phosphonate compounds, the method for pharmaceutical composition and disposal abnormal calcium and phosphate metabolism | PROCTER & GAMBLE PHARMA (US) | 1994-05-18 | — | — | CN | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040138197-A1 | Therapeutic use of aryl amino acid derivatives | CNR1, HCRTR1, HTR6 | ALDH1A1 776/4885ALOX15 1746/4885TRPA1 971/4885 |
| US-20110124705-A1 | PRODRUGS OF ALPHA-2-DELTA LIGANDS, PHARMACEUTICAL COMPOSITIONS AND USES THEREOF | CHRND, CHRNE, CHRNG | ALDH1A1 1298/4885ALOX15 2819/4885TRPA1 2964/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.